MATV — Mativ Holdings, Inc. · 2026-09-06 · Verdict: WATCH · Conviction 2
Price $12.66 (screen row, 2026-09-06 build; no live quotes in sandbox) · Mkt cap $698.7M · EV $1,606.9M · EV/LTM adj EBITDA 6.6x · LTM FCF yield 18.3% · Net debt $908.2M · ADV $7.5M Sources read: 10-K 2026-02-26 (Items 1, 1A, 7), 10-Q 2026-08-06 (MD&A), DEF 14A 2026-03-17, 8-Ks 2026-04-06, 2026-05-06 (x3), 2026-07-01, 2026-08-05, Form 4s (12m). No call transcript or prepared remarks were filed as exhibits; the Q2 "transcript" in the bundle is the EX-99.1 press release.
1. What the business actually does
Mativ turns fibers, resins and chemicals into engineered media (nonwovens, films, specialty paper, netting), then coats and converts it to customer specification across 34 plants and 100-plus countries. Filtration & Advanced Materials is 39% of 2025 revenue; Sustainable & Adhesive Solutions, mostly tapes, labels, liners and specialty paper, is 61%. No customer exceeds 10% of net sales (10-K 2025, Item 1). It is the 2022 Schweitzer-Mauduit / Neenah merger.
2. Why it is mispriced — the edge case
The edge is a screen artifact with a real origin. CY2025 GAAP operating profit is a $384.4 million loss, almost all of it a $411.9 million non-cash goodwill impairment, which makes the company uncomputable on EV/EBIT. The 10-K says the interim test was run "primarily in response to a sustained decline in the Company's share price" (Item 1A): the stock caused the write-down, not the cash flows. Excluding it, FAM earned $52.1 million of operating profit and SAS $85.6 million, up 88.5% (Item 7).
That edge has largely been arbitraged away in eight weeks. Form 4s show shares at $7.57 on 2026-07-01 and an officer disposition at $11.89 on 2026-09-01; at $12.66 the stock is up roughly two thirds off July and 13% below its 52-week high. The sellers of the GAAP wreckage have mostly finished, which is why this is not an IDEA today.
3. Unit economics and growth
Revenue is flat: FY2025 sales $1,987.0 million (+0.3%), H1 2026 $1,011.4 million (+0.1%), with H1 volume/mix negative 3.7% against price of 2.0% and currency of 1.8% (10-Q Q2 2026). The earnings improvement is entirely price over cost plus cost cuts. Q2 adjusted EBITDA was $75.0 million, up 12%, at a 14.1% margin, up 130 basis points (8-K 2026-08-05, EX-99.1), and H1 SG&A fell 7.6% under a plan targeting $15 to $20 million of further savings by end-2026 (10-K 2025, Item 1).
The segment split runs the wrong way for a quality story. In Q2 the higher-value FAM grew adjusted EBITDA just 1.4% to $35.4 million after a 41.2% jump in Q1, on organic sales down 0.1%, while SAS grew 18.8% to $50.5 million (8-Ks 2026-05-06, 2026-08-05). The franchise that would justify a specialty multiple is stalling while the commodity-adjacent half takes the windfall.
On the recast 2025 schedule (8-K 2026-05-06, EX-99.1), LTM adjusted EBITDA is $242.8 million and LTM free cash flow $127.7 million, an 18.3% yield. That yield is flattered: FY2025 capex of $40.0 million was 51% of the $77.7 million of segment depreciation and H1 2026 capex annualises to 41%, so some free cash flow is borrowed from the asset base. An off-balance-sheet Receivables Sales Agreement, unsized in the bundle, also supplements cash flow.
4. Balance sheet and capital allocation
At 30 June 2026 net debt was $908.2 million, credit-agreement leverage 3.8x versus a 5.00x covenant, liquidity $345.5 million (10-Q Q2 2026). The April 3, 2026 Ninth Amendment refinanced into a $305 million revolver, $89.9 million Term A and $500 million Term B, pushing the nearest maturity to the 8.000% notes due October 2029 (8-K 2026-04-06). That removed a real 2027 wall, but not cheaply: Term B now bears 3.50% to 4.50% margins against the old 2.75%. Covenants tighten to 4.50x net leverage in June 2027 and 4.00x in June 2028, and coverage against a $77 million interest run-rate is roughly 3.2x versus a minimum rising to 3.00x. Real headroom, not generous.
The $0.10 quarterly dividend costs about $22 million a year; there is no buyback and share count rose 0.9%. Directors and officers own 1.75% of the class, and Form 4s show zero open-market purchases by any insider in twelve months at prices as low as $7.57. PSUs are at least earned on free cash flow as a percentage of sales and ROIC, under a relative TSR modifier (DEF 14A 2026).
5. Management: what they said vs what they did
Shruti Singhal became CEO in March 2025 after his predecessor and the CFO both departed, costing $7.6 million of separation charges (10-K 2025, Item 7). In the Q1 release he said favourable price versus input costs would "continue for the balance of the year" (8-K 2026-05-06, CEO); Q2 delivered exactly that, and he called it "our strongest financial quarter since becoming Mativ four years ago" (8-K 2026-08-05, CEO). SG&A has fallen three years running ($263.9M, $233.8M, $228.7M), so the cost promises were kept. What has not happened is any conversion into volume, and the company issues no numeric guidance at all.
6. Valuation
EV is $1,606.9 million, 6.6x LTM adjusted EBITDA, and net debt is 57% of it, so one turn of multiple is $4.53 per share, 36% of the price. This is a multiple bet, not a cash-flow bet.
Base (50%): H2 grows modestly on a harder comp, FY2026 EBITDA $250 million at 6.75x, net debt $870 million. Value $14.81, up 17%. Bull (25%): the final cost wave lands and volumes stop falling, FY2027 EBITDA $270 million at 8.0x, net debt $800 million. Value $24.64, up 95%. Bear (25%): the price/cost spread reverses after a fourth year of price against falling volume, EBITDA $225 million at 5.5x, net debt $920 million. Value $5.75, down 55%. Probability-weighted $15.01, about 19% above the price.
Reverse DCF: the price implies roughly $145 million of perpetual unlevered free cash flow, capex normalised to depreciation, capitalised at about 9% with zero growth. That is a fair reading of flat revenue and falling volume, not a bargain.
7. Catalysts and timeline
Q3 results in early November are the first clean test of whether the spread survives a hard comp (H2 2025 adjusted EBITDA was $120.3 million against H1's $104.4 million). Deleveraging toward 3.0x through 2027 would mechanically re-rate the stub.
8. Risks and pre-registered kill criteria
The margin gain is price-led while volumes fall, so it reverses if customers resist; capex at half of depreciation cannot persist; further impairment remains possible (10-K 2025, Item 1A).
- Consolidated adjusted EBITDA margin below 12.0% in two consecutive quarters (Q2 2026: 14.1%).
- Credit-agreement net leverage above 4.25x at any quarter end (3.8x at 30 June 2026).
- FAM segment adjusted EBITDA down year over year in two consecutive quarters.
- Capex below 60% of depreciation through FY2027 with adjusted EBITDA flat or lower.
9. Verdict and one-paragraph summary
WATCH, conviction 2. A $411.9 million goodwill impairment, triggered by the falling share price itself, buried a business generating $242.8 million of LTM adjusted EBITDA and $127.7 million of free cash flow, and April's refinancing pushed the nearest maturity out to 2029. But the market has already done most of that work: the stock is up about two thirds from $7.57 in July, leaving 6.6x EV/EBITDA on a company with flat revenue, volumes down 3.7%, and a margin gain that is entirely price over cost plus SG&A cuts, concentrated in the lower-quality segment while the filtration franchise stalls. One turn of multiple is 36% of the share price, free cash flow is flattered by capex at half of depreciation, no insider has bought on the open market in twelve months, and there is no guidance at all. A probability-weighted $15 against $12.66 does not pay for that left tail. If the spread holds through the November print and leverage keeps falling, this becomes an IDEA.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.